We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

103 hedge funds and large institutions have $589M invested in Relmada Therapeutics in 2026 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 27 increasing their positions, 25 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

570% more call options, than puts

Call options by funds: $3.66M | Put options by funds: $546K

270% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 10

136% more capital invested

Capital invested by funds: $249M → $589M (+$340M)

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

32% more funds holding

Funds holding: 78 → 103 (+25)

10.36% more ownership

Funds ownership: 70.41% → 80.77% (+10%)

8% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 25

Holders
103
Holders Change
+25
Holders Change %
+32.05%
% of All Funds
1.27%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
37
Increased
27
Reduced
25
Closed
10
Calls
$3.66M
Puts
$546K
Net Calls
+$3.11M
Net Calls Change
+$1.23M

Top Buyers

1
VA
VR Adviser
New York
+$22.9M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$17.9M
3
RCM
RA Capital Management
Massachusetts
+$13.9M
4
Millennium Management
Millennium Management
New York
+$10.6M
5
SSC
Spruce Street Capital
New York
+$10.3M

Top Sellers

1
B
Braidwell
Connecticut
-$7.64M
2
Corient Private Wealth
Corient Private Wealth
Florida
-$3.4M
3
IC
Ikarian Capital
Texas
-$1.8M
4
Ameriprise
Ameriprise
Minnesota
-$1.56M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$1.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
Acadian Asset Management
26
Acadian Asset Management
Massachusetts
$4.96M +$879K +185,822 +35%
Goldman Sachs
27
Goldman Sachs
New York
$4.87M +$2.62M +554,039 +382%
Qube Research & Technologies (QRT)
28
Qube Research & Technologies (QRT)
United Kingdom
$4.55M +$2.36M +497,804 +320%
CC
29
Commodore Capital
New York
$4.41M +$3M +633,901 New
SC
30
Stempoint Capital
New York
$4.16M +$2.83M +597,409 New
Point72 Asset Management
31
Point72 Asset Management
Connecticut
$3.51M +$1.5M +317,443 +169%
ACM
32
ADAR1 Capital Management
Texas
$3.15M +$1.99M +421,052 +1,364%
IHAM
33
Integral Health Asset Management
New York
$3.13M +$2.13M +450,000 New
VFT
34
Vanguard Fiduciary Trust
Pennsylvania
$3.13M +$2.13M +449,811 New
DMKJ
35
David M. Knott Jr
$3.06M +$2.08M +439,300 New
WP
36
Woodline Partners
California
$2.93M +$1.99M +421,052 New
BC
37
Birchview Capital
Vermont
$2.85M +$1.94M +409,387 New
Two Sigma Investments
38
Two Sigma Investments
New York
$2.84M -$779K -164,740 -29%
State Street
39
State Street
Massachusetts
$2.48M +$171K +36,220 +11%
PCM
40
Parsons Capital Management
Rhode Island
$2.45M +$423K +89,500 +34%
JHC
41
Jones Hill Capital
New York
$2.39M +$1.62M +342,752 New
SGM
42
Seven Grand Managers
New York
$2.2M +$1.49M +315,788 New
AI
43
AdvisorShares Investments
Maryland
$2.06M -$112K -23,638 -7%
EP
44
Eversept Partners
New York
$1.93M +$1.31M +277,899 New
Balyasny Asset Management
45
Balyasny Asset Management
Illinois
$1.76M -$1.4M -295,397 -54%
Deutsche Bank
46
Deutsche Bank
Germany
$1.56M – – –
Jane Street
47
Jane Street
New York
$1.54M -$232K -49,140 -18%
ABG
48
Ally Bridge Group
New York
$1.47M +$996K +210,525 New
DP
49
Diadema Partners
New Jersey
$1.4M -$892K -188,553 -48%
Morgan Stanley
50
Morgan Stanley
New York
$1.38M +$644K +136,106 +218%
1
2
3 4 5

RLMD Hedge Fund Activity: Q1 2026 in Review

103 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q1 2026, worth a combined $589M — up 136% from $249M a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new RLMD positions and 10 closed out — a net gain of 27 holders — while 27 added to existing stakes and 25 trimmed.

The largest buyer was VR Adviser, opening a new position worth an estimated $22.9M. The largest seller was Braidwell, exiting entirely with an estimated $7.64M sold.

  • 103 institutional investors held Relmada Therapeutics (RLMD) as of Q1 2026, up from 78 in Q4 2025.
  • Funds reported $589M of Relmada Therapeutics stock for Q1 2026, up 136% quarter-over-quarter.
  • 37 funds opened new Relmada Therapeutics positions in Q1 2026 and 10 closed out, a net change of +27 holders.
  • The largest Relmada Therapeutics buyer in Q1 2026 was VR Adviser, an estimated $22.9M added.
  • The largest Relmada Therapeutics seller in Q1 2026 was Braidwell, an estimated $7.64M sold.

Based on aggregated 13F filings for Q1 2026.